UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000028816 |
|---|---|
| Receipt number | R000032983 |
| Scientific Title | Oral Testofen, L-citrulline, Resveratrol, and Caffeine supplementation study for sexual function: randomized, double blind, placebo-controlled crossover pilot study. |
| Date of disclosure of the study information | 2017/08/25 |
| Last modified on | 2019/03/13 21:20:57 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Oral Testofen, L-citrulline, Resveratrol, and Caffeine supplementation study for sexual function: randomized, double blind, placebo-controlled crossover pilot study.
Acronym
Testofen, L-citrulline, Resveratrol, and Caffeine supplementation study for sexual function.
Scientific Title
Oral Testofen, L-citrulline, Resveratrol, and Caffeine supplementation study for sexual function: randomized, double blind, placebo-controlled crossover pilot study.
Scientific Title:Acronym
Testofen, L-citrulline, Resveratrol, and Caffeine supplementation study for sexual function.
Region
| Japan |
Condition
Condition
Sexual Dysfunction
Classification by specialty
| Urology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
Improving sexual function
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Pragmatic
Developmental phase
Not applicable
Assessment
Primary outcomes
International Index of Erectile Function
Key secondary outcomes
Salivary testosterone
Base
Study type
Interventional
Study design
Basic design
Cross-over
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
YES
Dynamic allocation
YES
Institution consideration
Institution is not considered as adjustment factor.
Blocking
YES
Concealment
Central registration
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Food |
Interventions/Control_1
Oral Testofen, L-citrulline and Resveratrol 2-week supplementation
Interventions/Control_2
Oral placebo 2-week
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 30 | years-old | <= |
Age-upper limit
| 49 | years-old | >= |
Gender
Male
Key inclusion criteria
Score less than or equal to 25 of International Index of Erectile Function erectile function domain, despite use of PDE5i.
Score less than or equal to 3 of items Ejaculatory frequency, Desire frequency, or Desire level.
Key exclusion criteria
Chickpea allergy
Contraindication for PDE5i
Without nerve sparing, radical prostatectomy
Target sample size
20
Research contact person
Name of lead principal investigator
| 1st name | Masato |
| Middle name | |
| Last name | Shirai |
Organization
Juntendo University Urayasu Hospital
Division name
Department of Urology
Zip code
2790021
Address
2-1-1, Tomioka, Urayasu. Chiba, Japan
TEL
+81473533111
masatos@juntendo-urayasu.jp
Public contact
Name of contact person
| 1st name | Masato |
| Middle name | |
| Last name | Shirai |
Organization
Juntendo University Urayasu Hospital
Division name
Department of Urology
Zip code
2790021
Address
2-1-1, Tomioka, Urayasu City, Chiba, Japan
TEL
+81-47-353-3111
Homepage URL
masatos@juntendo-urayasu.jp
Sponsor or person
Institute
Juntendo University Urayasu Hospital
Institute
Department
Personal name
Funding Source
Organization
None
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Men's health clinic, Tokyo
Name of secondary funder(s)
None
IRB Contact (For public release)
Organization
Institutional Review Board, Juntendo University Urayasu Hospital
Address
2-1-1, Tomioka, Urayasu City, Chiba, Japan
Tel
+81-47-353-3111
rinri-urayasu@juntendo-urayasu.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
順天堂大学浦安病院（千葉県）Juntendo University Urayasu Hospital
メンズヘルスクリニック東京（東京都）Men’s health clinic, Tokyo
Other administrative information
Date of disclosure of the study information
| 2017 | Year | 08 | Month | 25 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
20
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2017 | Year | 08 | Month | 25 | Day |
Date of IRB
| 2017 | Year | 10 | Month | 17 | Day |
Anticipated trial start date
| 2017 | Year | 10 | Month | 17 | Day |
Last follow-up date
| 2019 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2017 | Year | 08 | Month | 24 | Day |
Last modified on
| 2019 | Year | 03 | Month | 13 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032983
| Research Plan | |
|---|---|
| Registered date | File name |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| Research case data | |
|---|---|
| Registered date | File name |
